Trialsinsulin lisprolyumjeveli lillytype 2 diabetes

Lilly completes Phase 4 safety study of Lyumjev in Indian type 2 diabetes patients

The 26-week open-label single-arm trial assessed insulin lispro-aabc safety, with each participant followed about 33 weeks.

By Priya Raman · Science Reporter

Sep 28 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT06370715, sponsored by Eli Lilly, was a multicenter open-label single-arm Phase 4 study of insulin lispro-aabc in adults with type 2 diabetes in India, started 18 April 2024 and now listed as completed.
02Registry-level detail only; the study design was a local safety commitment rather than a comparative efficacy trial.
03No results are posted in the registry entry, and the single-arm open-label design limits what can be concluded about relative safety.

From the source

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
NCT06370715 · PHASE4 · COMPLETED · Sponsor: Eli Lilly and Company · Conditions: Diabetes Mellitus, Type 2.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT06370715